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See Article, pages 1299–1304Prescribing medication and explaining how to take it, what side
effects and beneﬁts it may have, are core activities of every phy-
sician and hepatologist. It has been shown that straightforward
review of the patients’ medication intake is not conducted rou-
tinely [1]. Physicians rarely ask their patients about their adher-
ence to the prescribed medication [2]. At the same time, the
increasing use of potent anti-infective therapy has clearly dem-
onstrated the importance of patient adherence. Nowadays, clini-
cal studies have proposed different means of measuring
adherence as objectively as possible. However, it appears that
adherence rates assessed with these measures are unsatisfactory
[3,4]. Objectively measured adherence may differ quite substan-
tially from self-reported medication adherence [5].
Many different factors may inﬂuence adherence to drug regi-
mens [6,7] (summarized in Table 1): on the one hand, factors
attributable to the patients such as psychiatric disorders, psycho-
logical distress, presence of depression or anxiety, lower formal
education or communication barriers, marital status, older or
younger age, poverty, geographic clustering [8] and many more
have been shown to have a negative impact on drug-adherence.
On the other hand, a favorable view about the goals of treatment
and informed consent improve drug-adherence. In addition, there
are factors having an impact on adherence attributable to the
treating physician: prescription of complex therapeutic regimens
containing many different pills and/or time points [7], ineffective
communication about effects and possible side effects of the
medication as well as incomplete information about the disease
itself and the therapeutic regimen may all negatively affect
adherence. Detailed education of patients has been shown to be
particularly important as patients may have very different ideas
of the disease’s pathogenesis and possible inﬂuencing factors
[9]. These discrepancies of information level between laymen’s
views and physicians’ views have a direct negative effect on
adherence.
In addition to factors attributable to the patient or the physi-
cian, there are disease-related factors that are speciﬁcallyJournal of Hepatology 20
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Open access under CC BY-NC-ND license.relevant in the setting of chronic diseases. Although these factors
may be difﬁcult to differentiate from patient-related factors, they
deserve additional attention as their consideration may facilitate
and improve treatment success.
In chronic liver diseases such as autoimmune hepatitis (AIH),
drug adherence can be particularly difﬁcult, and is at the same
time particularly important. Untreated AIH has a poor prognosis,
while adequate treatment results in excellent prognosis [10,11].
Patients may be alienated by the unknown pathogenesis with
an often asymptomatic or oligosymptomatic course and the need
of potent immunosuppressive treatment. Sudden ﬂares without
trigger may occur and unsettle the patient further. Reading the
instruction leaﬂets of the most frequently prescribed medications
prednisone, azathioprine or mycophenolate mofetil is unlikely to
encourage the patient’s motivation for drug adherence. The long
list of potential side effects as well as the subjectively perceived
and objectively possible consequences of initially high steroid
doses may frighten patients.
The study by Sockalingam and colleagues [12] in this issue
focuses on patient-related factors by analyzing a cohort of 57
well-deﬁned patients suffering from AIH: these patients treated
for AIH at a tertiary care center were asked to report their adher-
ence on a visual scale from 1 to 100. In addition they were asked
to complete different validated questionnaires regarding their
anxiety level (GAD7, Generalized Anxiety Disorder-7), presence
of depression (PHQ9, Patient Health Questionnaire-9) and rela-
tionship style (ECR-16; Experiences in Close Relationship Scale).
Treatment response to standard immunosuppressive treatment
was determined by liver biochemistry and immunoglobulin G
levels. Not surprisingly, treatment response was associated with
higher self-reported adherence underlining that the conventional
treatment with azathioprine or mycophenolate mofetil in addi-
tion to prednisone is effective when actually taken.
In general, adherence was rather high in this group of patients
with more than 80 percent of the patients reporting drug-adher-
ence of more than 80%. This ﬁnding compares favorably to other
diseases in a non-transplant setting [3], especially when taking
into account that many of these patients were probably asymp-
tomatic. The results, however, may be biased by the fact that
patients attending a tertiary care center are likely to be more
motivated than the average patient seeing a general practitioner.
In addition, there is a positive selection bias as study12 vol. 57 j 1168–1170
Table 1. Factors inﬂuencing drug adherence.
Type of factor
adherence
Possible measures to influence drug-
Patient-related factors Psychiatric disorders Screening for the presence of factors that could 
influence drug adherence
Psychological distress, presence of depression or 
anxiety, avoidant relationship style, etc.
Acknowledgement of additional diseases and/or 
conditions, specific treatment if possible
Lower formal education
Poverty
Communication barriers (language, vision, etc.) 
and physical impairment
Marital status and social support
Older age/younger age
Physician-related factors Prescription of complex therapeutic regimen If possible, choice of less complex therapeutic 
regimen, review of medication taken
Ineffective communication about effects and/or 
side-effects of the drugs
Education about effects and side effects, review 
of medication taken
Incomplete education about the disease Education about the disease, brochures. 
Follow-up appointment to review questions
Inadequate follow-up and discharge planning Information about follow-up appointments and 
further plan
Disease-related factors Chronic disease Education about the disease, brochures
Asymptomatic disease Follow-up appointment to review questions
Unpredictable course of disease Effective communication about effects and 
side-effectsPotent treatment associated with side-effects 
unavoidable
Pharmacist/nurse-related factors Ineffective communication about effects and/or 
side-effects of the drug
Improved communication
JOURNAL OF HEPATOLOGYparticipation was voluntary, thus probably including primarily
more cooperative and motivated patients.
Evidently, non-responders had more anxiety symptoms and
higher ECR avoidance scores. Anxiety is often associated with
misconceptions of the pathogenesis and course of diseases and
may increase with poor treatment response, but may also be a
predisposing factor for non-adherence. Isolating causality is of
course challenging and problematic. The current study was
designed to analyze adherence rather than to answer this more
philosophical question, but the fact that ECR avoidance scores
are one expression of a relationship style and an almost stable
personality trait not easily inﬂuenced by external factors, sug-
gests that anxiety was present in patients prior to the diagnosed
AIH. Among the treatment non-responders in this study, 25%
reported adherence of less than 80% on a visual analogue scale.
These patients showed higher scores on the GAD7, PHQ9 and
ECR-avoidance score in addition to having worse laboratory out-
comes compared to the patients reporting adherence ofP80%. It
is important to point out that the current study did not question
patients about their reasons for non-adherence, which would
yield important information for planning future interventional
studies. Do patients simply forget to take their pills, as is being
reported to be a major reason in many other adherence studies,
or are there other reasons such as concerns about side effects,
feeling less control over their lives and poor life satisfaction?
[13,14].
Drug-adherence is rarely discussed with patients, and physi-
cians may not be sufﬁciently aware of this problem. PoorJournal of Hepatology 2012drug-adherence may endanger patients for two reasons: ﬁrstly,
they have an inefﬁcient ﬁrst-line treatment that may jeopardize
recovery and put them at risk for progression of AIH. Secondly,
poor treatment response is mostly misinterpreted as non-
response rather than non-adherence and therefore typically trig-
gers adaptation of immunosuppressive treatment. Higher steroid
doses, as nicely shown in this study, may be associated with
higher rates of depression. Administration of more potent and
potentially hazardous agents such as calcineurin inhibitors or
cyclophosphamide may cause an increase in anxiety in addition
to causing possible new side effects. These measures are
therefore counterproductive in a patient who may have been
non-adherent to ﬁrst-line treatments.
Solving this dilemma is certainly not easy and will require
talking to patients about drug adherence as well as trying to
identify and address factors that may negatively inﬂuence
drug-adherence. Gently assessing adherence in a way that will
not embarrass the patient or lead them to deny their non-
adherence can help identify patients at risk. Careful education
of patients has been shown to positively impact anxiety levels
e.g., in preoperative settings [15] and, at the same time shows
substantial effect on drug adherence [16]. Ideally, objective mea-
sures of drug adherence should be put in place, but it is certainly
unrealistic to refer to clinic-based pill counts, electronic systems
or other technical means of control. Measurements of 6-thiogua-
nine-nucleotide levels that reﬂect azathioprine adherence to a
certain extent are possible, but certainly do not replace a trustful
relationship between a chronically ill patient and their physician.vol. 57 j 1168–1170 1169
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Implementation of follow-up actions, incentives or perhaps
eTools to help patients [17,18] will improve patients’ adherence
and also their disease progression. The importance of drug adher-
ence should be openly addressed and combined with education
and information on the disease and the rationale of treatment.
Having identiﬁed this critical problem in the care of patients suf-
fering from AIH, the study demonstrates that additional research
is necessary to investigate the physician-related and disease-
related factors having an impact on drug-adherence. Further-
more, studies examining interventions in order to improve
adherence are necessary.
Chronic diseases ask for patient autonomy and shared deci-
sion-making. Examining adherence openly in a non-accusing
manner should be a routine part of every visit as well as identi-
ﬁcation of factors that may predispose for poor adherence – not
only in patients suffering from AIH. Tackling these factors may
be difﬁcult and time-consuming but worthwhile, as there are
multiple studies suggesting increases in drug adherence lead to
possible reduction of total health care cost [19,20] and hopefully
also better patient-physician relationships as well as healthier
patients.Conﬂict of interest
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